third protein, the acid-labile subunit (ALS).
1,2 Formation of these ternary complexes (TC) prolongs the half-life of IGFs and is therefore a major determinant of circulating concentrations. 1 The stability of the complexes also makes IGF-I a good diagnostic marker of growth hormone excess. In adult humans, ALS circulates in excess of the TC and is therefore not a limiting factor for TC formation. 3 One study demonstrated that ALS was a limiting factor for TC formation in healthy cats, while in diabetic cats with high IGF-I concentrations, ALS apparently circulated in excess. 4 Measurement of feline IGF-I is mainly used as a screening marker for acromegaly, which is almost exclusively diagnosed in cats with diabetes mellitus (DM). 5 Feline DM is considered to be similar to human type 2 DM and is characterized by insulin resistance and beta-cell failure. 6 The insulin-secreting capacity of feline beta-cells is blunted during hyperglycemia 7 and insulin concentrations at diagnosis of DM are usually low. 8, 9 Despite low insulin concentrations at diagnosis, cats can go into remission, defined as independence of insulin treatment ≥4 weeks. 10 Insulin concentrations at diagnosis do not predict remission. 10, 11 Insulin treatment of feline DM has been observed to increase IGF-I, 12, 13 which normalized faster in cats achieving remission. 13 As in other species, feline IGF-I concentrations appear to be influenced by nutritional status. 14 Improved understanding of the IGFsystem and the effect of insulin treatment is therefore essential for interpretation of IGF-I measurements in cats with DM.
The aim of this study was to further characterize the IGF-system evaluations and elevated fructosamine (>350 μmol/L). Cats were excluded from the study if they were pregnant or age <1 year.
For evaluation of IGF-binding profiles, an initial blood sample was collected from 17 diabetic cats. In addition, samples from healthy cats used for a previous study 15 were eligible for the laboratory work.
These cats were considered healthy based on a questionnaire, physical exam, and a basic biochemical profile (glucose, fructosamine, creatinine, ALT, albumin, protein). For IGF-binding profiles, 7 samples from cats with DM and 13 healthy cats were chosen to represent at range of IGF-I concentrations in both healthy and diabetic cats, thereby excluding 10 of the DM cats ( Figure 1 ). Insulin-like growth factor-I concentrations did not differ between excluded and included cats (P = .65). Six of the cats with DM were sampled before insulin treatment and 1 cat was receiving insulin glargine.
Twenty-four cats diagnosed with DM but not yet on insulin treatment were enrolled in the longitudinal study. A management regime that included insulin treatment was required for inclusion. Cats were followed for a year from inclusion in the study or until remission, death, or loss to follow up. Blood samples were taken 5 times: before first insulin injection (T0), after 2-4 weeks (T1), 8-10 weeks (T2), 5-7 months (T3), and 10-13 months (T4). At T0 cats were fasted for at least 12 hours, and at T1-T4 for at least 5 hours. At T1-T4, all cats were given insulin q12h and blood sampling was performed by venipuncture into tubes without anticoagulant. The duration of effect of insulin glargine in cats is estimated to be 11 hours. 16 Therefore, to minimize the interference of insulin glargine in the insulin assay, blood was taken just before the next q12h insulin injection. At every sampling occasion, the veterinary practitioner performed a standardized clinical examination and completed a questionnaire. Body composition was evaluated by body condition score (BCS) and graded 1-5 with 1 being underweight and 5 overweight. 17 The treating veterinarian FIGURE 1 Flow-chart of study design decided about additional diagnostic tests and thus not all cats had the same diagnostic-work-up.
Remission from DM was defined as no insulin treatment for 1 month, no clinical signs of DM and fructosamine concentrations within the reference interval (<350 μmol/L). Owners of cats that were euthanized during the study (n = 4) or after (n = 2) were asked for permission for postmortem examination and all but one gave this permission. Postmortem examinations were performed by the same board-certified pathologist. Early in the study period, CT with contrast enhancement of the pituitary gland was done in 1 cat with IGF-I > 1000 ng/mL, when anaesthetized for dental treatment.
| Analytical procedures
Blood samples were centrifuged within 30-60 minutes of sampling.
Serum was aliquoted into 2 tubes. One aliquot was sent by post at ambient temperature for analysis of glucose and fructosamine at the Clinical Pathology Laboratory at the Swedish University Animal Hospital. Glucose was analyzed using hexokinase/glucose-6-phosphate dehydrogenase (Glucose, Architect c Systems, Abbott Diagnostics, Illinois) and fructosamine by the nitrotetrazolium blue-method (ABX Pentra, Horiba group, Montpellier, France) using a standard biochemistry instrument (Architecht c4000, Abbott Diagnostics, Illinois). The laboratory reported intra-and inter-assay CVs for glucose of 0.6% and 1.1%, respectively, and for fructosamine 0.2% and 1.6%, respectively. The laboratory reported that serum glucose concentrations varied between −0.3% and 6.6% (n = 7 samples) when stored at room temperature for 2 days and that fructosamine concentrations varied between −3.9% and 4.1% (n = 3 samples) when stored at room temperature for 3 days. All samples arrived at the laboratory within 2 days.
The other serum aliquot was immediately frozen at −20 C, or kept at 2 C-4 C and frozen within 20 hours, and used for analysis of insulin and IGF-I. Feline insulin concentrations are stable for 4 days when stored at 2 C-4 C. 9 Insulin-like growth factor-I concentrations in samples (n = 2) stored at 2 C-4 C and analyzed after 3 and 6 days varied between −1.7% and 6.0% compared with baseline. Insulin-like growth factor-I and insulin were measured with ELISAs (Feline Insulin ELISA, Mercodia, Uppsala, Sweden; IGF-I ELISA, Mediagnost, Reutlingen, Germany) previously validated for use in cats. 9, 15 There is a cross-reactivity of 8.4% for insulin glargine in the feline insulin ELISA. 18 Intra-and inter-assay CVs of the insulin assay were 2.0%-5.8% and 7.6%-13.7%, respectively. Intra-and inter-assay CVs of the IGF-I assay were 2.4%-4.8% and 3.6%-5%, respectively. For both ELISAs, multiple samples from the same cat were analyzed together on the same ELISA plate.
| Size-exclusion chromatography
Size separation chromatography was performed on the single serum samples from healthy cats (n = 13) and diabetic cats (n = 7), as well as on samples from diabetic cats sampled at T0 and T1 (n = 7 Fractions were collected every 60 seconds and dried by vacuum concentration. The fractions were analyzed with the IGF-I ELISA according to the manufacturer's recommendation except that assay buffer was added directly to the dried fractions.
| Mass spectrometry
A targeted mass spectrometry (MS)-based method, previously validated for cats, 20 was applied to determine the concentrations of IGF-I, IGF-II, IGFBP-3, and IGFBP-5 in 3 cats with DM later achieving remission. Analyses were performed in serum at T0 and T1 exactly as described by Sundberg et al. 20 Briefly, the serum proteins were digested with trypsin and isotopically labeled internal standards, 
| Predictors of IGF-I concentrations
To evaluate factors associated with IGF-I concentrations, a linear mixed-effect model was built using the statistical software R. 21 Potential predictors were age, concurrent diseases, days from T0, insulin, fructosamine, BCS, and weight. Akaike Information Criteria and Pvalues were evaluated during modeling and predictors that did not contribute significantly to the model (P > .10) were excluded. Residuals were evaluated for normal distribution, homoscedasticity, and linearity with respect to the predictors. Preliminary models showed nonnormality of residuals and insulin and fructosamine were hence transformed to the natural logarithmic scale.
| Predictors of remission
Predictors of remission were evaluated by univariate logistic regression and receiver operating characteristic (ROC) curves, to calculate area under the curve (AUC). Since remission of diabetes has been associated with tight glycemic control, 22 glucose, fructosamine, and insulin were considered potential predictors in addition to IGF-I. The statistical software R was used for logistic regression analyses. 21 3 | RESULTS
| IGF-binding forms and concentrations of IGFBP-3, IGFBP-5, IGF-II, and IGF-I by MS
Cats with DM used for evaluating IGF-binding forms were sampled once before insulin treatment and consisted of 2 castrated male cats, 3 castrated female cats, and 1 intact male cat. Cats were between 8.2 and 20 years old and weighed between 3.9 and 6.3 kg. One cat had received glucocorticoids intratumoural in a cutaneous mast cell tumor before being diagnosed with DM and had renal insufficiency. One cat had cremor dentis and was obese, and 2 had urinary tract infection.
No cat had elevated TT4. Glucose and fructosamine ranged from 351
to 600 mg/dL and 483 to 725 μmol/L, respectively. Healthy cats consisted of 5 castrated males, 5 castrated females, 1 intact male, and 2 intact females. Age ranged from 4.2 to 8.6 years and weight was between 3.0 and 7.1 kg. There was no significant difference in weight (P = .21) or IGF-I concentrations (P = .68) between healthy and DM cats used for size exclusion chromatography, but DM cats were significantly older (P < .001). Figure 2 shows the IGF-binding profiles in these 13 healthy cats and 6 diabetic cats sampled before insulin treatment, and presented for 3 equal IGF-I intervals generated based on a previously published reference interval for healthy cats Figure 5B) but not in those that did not achieve remission (P = .7, Figure 6B ). Concentrations of IGF-I, IGF-II, IGFBP-3, and IGFBP-5, all measured by MS, are shown in Figure 5 . In the 3 cats, which went into remission, IGFBP-3 concentrations increased between T0 and T1 (P = .03). IGF-II and IGFBP-5 did not differ between sampling occasions (P = .4 and P = .6, respectively). IGF-II was 2-8-fold higher than IGF-I.
The molar ratio of IGFBP-3 and IGFBP-5 to total IGFs was 0.55-1.1.
| Cats included in the longitudinal study
Seventeen males (16 neutered and 1 intact) and 7 females (all ovariohysterectomized) were eligible for the longitudinal study. During the study period cats were followed for a year (n = 11) or until remission (n = 7), death (n = 4), or loss to follow up at T2 or T4 (n = 2; Figure 1 ).
Concurrent diseases were diagnosed in 13 cats and consisted of heart disease (n = 2), hyperthyroidism (n = 3), urinary tract infection (n = 3)
of which 1 cat also had tooth resorption, pancreatitis (n = 2), chronic renal failure (n = 1), osteoarthritis (n = 1), and feline asthma (n = 1).
The cat with feline asthma was treated with fluticasone inhalation. In 18 of the 24 cats, TT4 was measured at diagnosis of DM. In the remaining 6 cats, TT4 was analyzed in samples taken at T0 and saved at −80 C and analyzed after study ending. One of these cats had high TT4 (64 nmol/L, reference interval 14-45 nmol/L), which was unrecognized during the study. Two cats that had previously been treated Veterinarians instructed owners to perform blood glucose curves at intervals varying from before every injection to 1 curve every 14 days.
These 15 cats, and the other 9 cats, were also monitored by fructosamine and clinical signs. The surviving cat with ketoacidosis had been treated with glipizide but did not respond to treatment and had concurrent hyperthyroidism. This cat and 1 additional cat with hyperthyroidism, were receiving oral antithyroid medication (thiamazole). At T0, 2 cats were scored as underweight (BCS 1-2), 10 cats as normal weight (BCS 3), and 12 cats as overweight (BCS 4-5).
Descriptive statistics for the cats are presented in Table 1 . Insulin-like growth factor-I concentrations increased significantly between T0 and T1 (P = .0001) but did not change significantly thereafter.
Seven cats went into remission during the study period, all within One cat sampled at T4 had serum insulin concentrations well above the other cats (Figure 4 ). At this sampling occasion, the cat had a glucose concentration of 58 mg/dL, fructosamine 478 μmol/L, and was on insulin glargine 0.6 IU/kg q12. The sample was reanalyzed twice with the same results.
| Predictors of IGF-I concentrations
The mean increase in IGF-I between T0 and T1 was estimated to 350 ng/mL (95% CI 200-500). It was included as an offset in the model for predictors of IGF-I concentrations to account for possible selection bias caused by fallout due to remission. Weight was positively correlated and fructosamine negatively correlated with IGF.
However, fructosamine and weight were negatively correlated and we excluded weight because fructosamine was found to be a better predictor based on Akaike Information Criteria and P-values. As seen in Table 2 , IGF-I concentrations were negatively associated with ln-fruc- 
| Predictors of remission
There was substantial overlap in IGF-I concentrations between groups at T0 and none of the biomarkers at T0 predicted remission. At T1, 22 diabetic cats remained in the study and of these 6 later went into remission. One cat achieved remission before T1 and was not available for the prediction model. IGF-I at T1 was associated with remission (P = .046) but glucose, fructosamine, and endogenous insulin were not (P = .11, P = .24, and . : n = 14, T4: n = 11). * Sample at remission is taken at least 1 month after insulin was withdrawn. ** One cat at T4 had insulin concentrations much higher than the others (7903 ng/L) and is not included in the graph observed to increase. It is therefore recommended that, when using IGF-I as a marker of GH status in cats with diabetes, the effect of insulin treatment on IGF-I should be taken into account. chose to use the same methodology as previously used for studying feline IGF-binding forms. 4 Labeled human IGFs have been used for detection of feline IGFBPs on western ligand blots. 4, 14, 15 There is a report of similar finding of IGF-I immunoreactivity detected mainly in the 150 kDa-peak, regardless the size of the 150 kDa and 30-50 kDa-peak, in children. 30 Insulin-like growth factor-I, IGF-II, IGFBP-3, and IGFBP-5 were also measured by MS in 3 cats at baseline, and after diabetes remission. In these animals the increase in IGF-I was accompanied by an increase in IGFBP-3 concentrations. Insulin-like growth factor-I and IGFBP-3 depend on each other for TC formation and stability in the circulation, which prolongs their half-lives. 1 The increase in IGFBP-3
| IGF-binding forms
and IGF-I may be explained by an increase in ALS, or a direct stimulatory effect of insulin treatment on IGF-I and IGFBP-3 in the presence of sufficient ALS. As in humans, 31 IGFBP-5 in these cats circulated in lower concentrations than IGFBP-3. In humans, binary complexes with IGFs and IGFBP-5 have a lower affinity for ALS than binary complexes with IGFBP-3. 27 If feline IGFBP-5 binary complexes have a similarly lower affinity for ALS, 27 our results suggest it is unlikely that IGFBP-5 is a major contributor to TC formation in the cat. In the 3 animals studied, IGF-II concentrations did not increase during insulin treatment. We speculate that IGF-II may be an important component of binary complexes in cats and more readily available to tissues. Nevertheless, we recommend caution in extrapolating what is known about the IGF-physiology and pathophysiology between species.
| Predictors of IGF-I during treatment
In our study IGF-I concentrations were positively associated with insulin concentrations up to 60 ng/L and negatively associated with fructosamine. In previous studies, weight has been associated with IGF-I in health and in diabetes. 14, 15, 32 In our study weight was excluded in the final model due to correlation with fructosamine and fructosamine gave a better model fit. The association between IGF-I concentrations, fructosamine, and insulin needs to be taken into account when interpreting IGF-I concentrations and our findings support previous recommendations that screening for acromegaly in diabetic cats should be done after initiation of adequate therapy. 33 There are likely multiple mechanisms underlying the association between insulin and IGF-I concentrations. Our results demonstrated a positive association at insulin concentrations up to 60 ng/L, which was lost at higher insulin concentrations. Since hepatic GH-receptors will stimulate IGF-I synthesis one explanation could be an effect of insulin on hepatic GH-receptor expression. 34, 35 One in vitro study found the effect of insulin on GH-receptor synthesis to be dosedependent, declining at higher insulin concentrations. 34 Insulin stimulates ALS concentrations 36, 37 and another possible explanation for the association between IGF-I and insulin is an effect of insulin on the circulating forms and therefore half-life of IGF-I. Like IGF-I, ALS is GH dependent 1 and any effect on hepatic GH receptors may also play a role in regulating its synthesis.
One cat had very high insulin concentrations when sampled after a year of treatment with insulin glargine. The reason for the remarkably high insulin concentration was not determined. One possibility is interference of insulin antibodies toward insulin glargine, which could be measured in the insulin assay. In humans with DM, a rare cause of hyperinsulinemic hypoglycemia is insulin antibodies. 38 Direct interference of insulin glargine in the assay is unlikely given a cross-reactivity 
| Prediction of remission
Glycemic control is considered the key factor for achieving remission in cats. 22, 39 In our study, high IGF-I concentrations 2-4 weeks after starting insulin treatment predicted remission of DM. Untreated DM may be regarded as a state of intracellular undernutrition. Insulin-like growth factor-I concentrations are decreased in states of poor nutritional status in cats as well as in humans. 14, 40 It is likely that initiation of insulin therapy increases IGF-I concentrations in part by an indirect effect, by promoting anabolism and reducing the catabolic state. It has been proposed that local IGF-I promotes survival of feline beta-cells and insulin production. 41 Insulin-like growth factor-I may by enhancing insulin action 42 contribute directly to glycemic control and therefore remission. The finding of increased serum IGF-I concentrations after initiation of insulin treatment in cats has been reported previously.
12,13
Because glycemic control is associated with increased remission rates 22 we decided to investigate glucose, fructosamine, and insulin, in addition to IGF-I, as predictors of remission. None of these predictors reached statistical significance or the same AUC as IGF-I in the statistical models. Cats can present with stress hyperglycemia which may have affected glucose measurements in some of the cats, 43, 44 and could explain why glucose did not perform better as a predictor.
Fructosamine concentrations are dependent on protein turn-over time and blood glucose concentrations and are generally considered to represent glycemic control during the last 1-2 weeks. 45, 46 It is possible that fructosamine could be a predictor at later time points, however there were too few cats left in the study to explore this possibility. In agreement with previous reports, 10,11 insulin concentrations were not different between the 2 groups and are not useful in the prediction of DM remission in cats.
| Implications for IGF-I as a screening tool for acromegaly
Although IGF-I concentrations were <1000 ng/mL in all cats at diagnosis, 33% of cats (8/24) reached levels >1000 ng/mL while on insulin treatment. This is a similar proportion to that reported in a study by Niessen et al. 24 None of the 8 cats with IGF-I > 1000 ng/mL had clinical features of acromegaly and 5/8 cats went into remission, 2/8 cats had fructosamine concentrations within the reference interval and 1 cat was euthanized with no findings of acromegaly post mortem.
However, in the study by Niessen et al 24 the majority of cats with DM and confirmed acromegaly did not present with phenotypical changes commonly associated with acromegaly making clinical features a less reliable diagnostic tool. In our study, acromegaly was excluded by diagnostic imaging or post mortem examination in 2/5 of cats with IGF-I > 1000 ng/mL that went into remission from diabetes. Remission from diabetes is exclusively described in acromegalic cats after treatment with hypophysectomy 47 or pasireotide. 48 Although we deemed it unlikely that the other 3 cats had acromegaly, it is theoretically possible. In a recent study, acromegaly was diagnosed in 3 cats without DM. 49 Different IGF-I immunoassays may not give the same concentration due to differences in type of calibration material, immunoreactivity, and extraction method for IGFBPs, which otherwise interfere in the assay. 15, 50 Given these observations we would suggest caution before using IGF-I values of 1000 ng/mL as a general cut-off for screening for acromegaly in diabetic cats.
| Strengths and limitations
Reverse causation and selection bias were minimized by the longitudinal study design, which is a clear strength of this study. However, only about one-third of the cats went into remission and hence we had low power for the remission prediction models. We did not have access to an external validation cohort, which is a limitation because we may be overestimating the AUC. The reported remission rate of feline DM is 14%-78%. 13, 22, [51] [52] [53] The remission rate in this study (29%) was in the lower range and may be due to inclusion of cats from both primary care and secondary care clinics, which may have Values are shown as median (interquartile range). differently motivated owners and differences in availability of specialists. The near-euglycemic protocol has been associated with higher remission rates in cats 22 ; however, the risk of hypoglycemia may hold back both veterinarians and owners from using this approach.
The treatment and investigations were decided by the treating veterinarians together with the cat owners. Therefore, another limitation is that we did not perform the same diagnostic work-up in all cats. It is possible that some cats had underlying diseases not diagnosed, which may affect IGF-I concentrations as well as IGF-binding profiles. However, animals included in this study are likely to be representative of diabetic cats in general practice. Even though the statistical model did not show any significant effect of other diseases, only 13 cats with DM had concurrent diseases, making the statistical power low. It is also possible that any effect on IGF-I concentrations and IGF-binding profiles may vary with different diseases; however, there were too few cats to perform these statistical calculations.
| CONCLUSIONS
In conclusion, IGF-I concentrations increase after initiation of insulin treatment for feline DM and were associated with markers of glycemic control. In cats that went into remission, the amount of 150 kDa 
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